Yahoo Finance

Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery

Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. This investment ...
Yahoo Finance

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...
FierceBiotech

Recursion's phase 2 brain disease trial yields scant evidence of efficacy

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
JSTOR Daily

RECURSIVE INTEGRAL METHOD FOR THE NONLINEAR NON-SELFADJOINT TRANSMISSION EIGENVALUE PROBLEM

The transmission eigenvalue problem is an eigenvalue problem that arises in the scattering of time-harmonic waves by an inhomogeneous medium of compact support. Based on a fourth order formulation, ...
Nasdaq

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...